Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
5(100.0%)
5Total
Phase 1(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT01838473Phase 1Completed

In-vivo Extraction of Lead, Cadmium and Tobacco Specific Nitrosamines From Swedish 'Snus' in Regular Snus Users

Role: lead

NCT01838460Phase 1Completed

Sublingual Nicotine Tablets Compared With Swedish Snus

Role: lead

NCT01369693Phase 1Completed

In-vivo Extraction of Pb, Cd and TSNA From Swedish Snus

Role: lead

NCT01249339Phase 1Completed

In-vivo Extraction of Pb, Cd andTSNA From Swedish Snus

Role: lead

NCT01182129Phase 1Completed

4 mg Nicotine Polacrilex Gum and Swedish Portion Snus

Role: lead

All 5 trials loaded